• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Clinical Data

Soccer ball flying into a net scoring a goal
Biotech

Sellas’ AML asset tied to 50% response rate in certain patients

Sellas’ investigational CDK9 inhibitor has scored in a midstage AML study, demonstrating an ORR of more than double the 20% goal.
Gabrielle Masson Jul 15, 2025 10:34am
An arrow incrementally going up stairs before pointing straight up Blue background

Rhythm’s obesity pill trial hits primary goal, sending stock up

Jul 9, 2025 10:21am
Goal disorientation and lack of vision

UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss

Jul 8, 2025 10:17am
Graphic image of an arrow nailing the bullseye of a target

Cogent hits primary endpoint, building case for Blueprint rival

Jul 7, 2025 9:16am
An arrow incrementally going up stairs before pointing straight up Blue background

Biokin, having landed BMS deal, posts ph. 3 bispecific ADC win

Jul 2, 2025 9:53am
long shot miss basketball hoop fail shoot

Organon axes 'biggest potential opportunity' after trial fail

Jul 2, 2025 8:43am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings